Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: social media

FDA Approves Tremfya (Guselkumab) for Adult Patients with Psoriatic Arthritis

Natasha Yetman  |  July 15, 2020

HORSHAM, PA—The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved Tremfya (guselkumab) for adult patients with active psoriatic arthritis (PsA), a chronic progressive disease characterized by painful joints and skin inflammation.1,2 Tremfya is the first treatment approved for active PsA that selectively inhibits interleukin (IL)…

Filed under:Biologics/DMARDsDrug Updates Tagged with:FDA approvalguselkumabU.S. Food and Drug Administration (FDA)

A Primer on the Management of Scleroderma Emergencies

Jason Liebowitz, MD, FACR  |  July 14, 2020

Patient with autoimmune disease may experience medical emergencies. Here is an overview of recognition and management of three emergent situations for patients with scleroderma: critical digital ischemia, scleroderma renal crisis and intestinal pseudo-obstruction…

Filed under:ConditionsSystemic Sclerosis Tagged with:intestinal pseudo-obstructionischemiaScleroderma Renal Crisis

Malignant Complications: Screening for Cancer in Rheumatic Diseases

Jason Liebowitz, MD, FACR  |  July 13, 2020

Cancer and autoimmunity have a complex relationship. In a presentation, Ami Shah, MD, MHS, discussed how to use autoantibodies as tools for cancer risk stratification, how to approach cancer screening in individuals with new-onset disease and more…

Filed under:ConditionsSystemic Sclerosis Tagged with:AntibodiesCancercancer riskScleroderma

We Make a Difference

Philip Seo, MD, MHS  |  June 15, 2020

“No!” she screamed. My niece just finished her first semester as a freshman at the University of St. Andrews in Scotland. If the institution sounds familiar to you, it may be because you remember a particularly famous graduate—William Windsor, who sometimes goes by his formal titles: Duke of Cambridge and heir to the British throne….

Filed under:ConditionsOpinionRheuminationsSpeak Out Rheum Tagged with:COVID-19

Transitioning to a Virtual Practice: Q&A with Lisa Criscione-Schreiber, MD, MEd

Carina Stanton  |  May 1, 2020

A quick shift to virtual teaching and patient care is just one of many changes rheumatologists at Duke University are adapting to during the COVID-19 pandemic…

Filed under:Practice Support Tagged with:coronavirusCOVID-19Practice Managementtelemedicine

Adapting Care for Pediatric Patients & Parents During the Pandemic: Q&A with Sangeeta Sule, MD, PhD

Susan Bernstein  |  May 1, 2020

Social distancing and telemedicine are creating unique challenges for pediatric rheumatologists to care for their patients—many of whom are 5 years old or younger. Sangeeta Sule, MD, PhD, discusses how her clinic is adapting…

Filed under:Conditions

Reimbursement Tips: Telemedicine & Coding in the Time of COVID-19

Kimberly Retzlaff  |  April 24, 2020

Humans may fear change as a general rule, but we’re adaptable when we need to be. In this era of COVID-19 and social distancing, medical practices and payers are adapting to an increased use of telemedicine, which enables providers to see their patients without being in a room with them. To cope, the Centers for…

Filed under:Billing/CodingConditionsPractice Support Tagged with:CodingCOVID-19telemedicine

Inflammation & Psych Issues: A Look at Potential Co-Morbidity

Mike Fillon  |  March 30, 2020

Rheumatic disease affects not just the body, but can also compound psychiatric disturbances, including depression, anxiety, fatigue and more, possibly making the underlying disease worse…

Filed under:Conditions Tagged with:comorbiditiesinflammationmindpsychiatric

Enemy at the Gates: The Emerging Threat of COVID-19

Philip Seo, MD, MHS  |  March 23, 2020

On Dec. 30, 2019, an ophthalmologist named Li Wenliang notified his colleagues about an illness that was reminiscent of severe acute respiratory syndrome (SARS) in a city in the Hubei province of China called Wuhan. As an ophthalmologist, this was not directly relevant to his practice; he merely wanted to warn colleagues that they might…

Filed under:ConditionsOpinionProfessional TopicsRheuminationsSpeak Out Rheum Tagged with:COVID-19Philip SeoRheuminationsSeo

Cannabinoids Show Potential in Pain Management

Mike Fillon  |  February 13, 2020

ATLANTA—The potential of cannabis‐based medicines is a hot topic, particularly as pain management therapy for arthritis and other conditions. However, confusion abounds regarding its therapeutic potential, how it can be administered and even the correct terminology to use. David P. Finn, PhD, professor of pharma­cology and therapeutics, and founding co-director of the Centre for Pain…

Filed under:AnalgesicsDrug UpdatesMeeting Reports Tagged with:2019 ACR/ARP Annual MeetingcannabinoidPain Management

  • « Previous Page
  • 1
  • …
  • 30
  • 31
  • 32
  • 33
  • 34
  • …
  • 49
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences